Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentarlandir UPPTA in Early COVID-19
NCT04911777Phase 2Unknown
- Sponsor
- SyneuRx
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pentarlandir UPPTA in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by SyneuRx. Primary endpoint: Change from baseline in viral genome at Day 14. Status: unknown.
02
Drugs
Pentarlandir UPPTA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04911777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911777.